XML 187 R37.htm IDEA: XBRL DOCUMENT v3.25.2
Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)
$ in Thousands
 10 Months Ended
Dec. 31, 2023
USD ($)
shares
Jun. 30, 2025
shares
Dec. 31, 2024
stockholder
shares
Mar. 07, 2023
USD ($)
shares
Merger with Sesen Bio        
Number of board seats | stockholder     7  
Entity common stock, shares outstanding immediately after merger (in shares) | shares 40,609,915 41,788,096 41,750,109  
Cash and cash equivalents       $ 37,873
Marketable securities       44,588
Prepaid expenses and other assets       1,316
Restricted cash       30
Accounts payable and accrued expenses       (3,499)
Total net assets acquired       80,308
Less: Transaction costs       (8,264)
Total net assets acquired less transaction costs       $ 72,044
Carisma Therapeutics Inc.        
Merger with Sesen Bio        
Number of board seats | stockholder     6  
Severance and personnel costs paid $ 4,600      
CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.        
Merger with Sesen Bio        
Business acquisition percentage of voting interests acquired (as a percent)       74.20%
Entity common stock, shares outstanding immediately after merger (in shares) | shares       40,254,666